Spinal Muscular Atrophy Ehlers-Danlos Syndrome Down Syndrome Epidermolysis Bullosa Prader-Willi Syndrome Neuromuscular Disorders Osteogenesis Imperfecta Heart Conditions Hypertrichosis Pompe Disease Kallmann Syndrome Metabolic Disorders Neurofibromatosis Dextrocardia BRCA1 Gene Situs Inversus 5-Alpha-Reduktase Deficiency Alpha-1 Antitrypsin Deficiency Cardiac Amyloidosis Limb-Girdle Muscular Dystrophy Causes Allergies Muscular Dystrophy Phenylketonuria Polycystic Kidney Disease Cardiac Conditions Mitochondrial Disease Symptoms Congenital Insensitivity to Pain Hereditary Angioedema Cleidocranial Dysplasia Cardiomyopathy Skeletal Muscle Disorders Coagulopathy Bone Marrow Donation Alternating Hemiplegia of Childhood Trisomy 13 Heart Disease Wiskott-Aldrich Syndrome Retinitis Pigmentosa Smith-Magenis Syndrome Leukocyte Adhesion Deficiency ERCC1 Deficiency Chromosomal Abnormalities Inherited Blindness Acondroplasia MTHFR Mutation Chromosome Abnormalities Hemochromatosis Hereditary Hemorrhagic Telangiectasia Nemaline Myopathy Physical Disabilities BRCA Gene Mutation Crouzon Syndrome Ektrodaktylie-Ektodermal-Dysplasie-Syndrom Congenital Myasthenia Syndrome Hypertrophic Cardiomyopathy Haemochromatosis Myostatin Deficiency Hyperphagia Autosomal Recessive Polycystic Kidney Disease Severe Combined Immunodeficiency Rare Diseases Turner Syndrome Comorbidities Fanconi Anaemia Optic Atrophy Sickle Cell Disease Chronic Pain Wilson's Disease Lysosomal Storage Disorders Trisomy Disorders Trisomy 18 Fanconi Anemia Duchenne Muscular Dystrophy Kidney Health Adenosine Deaminase Deficiency Thalassemia SMA Type 1 Motor Neurone Disease Optic Nerve Disorders HPDL Deficiency Skin Disorders Haemophilia Hirschsprung Disease Dwarfism Nervous System Disorders Blood Disorders McCune-Albright Syndrome Ectrodactyly Ectodermal Dysplasia Chromosomal Disorders Early-Onset Dementia Hemophilia Cardiovascular Diseases
The move secures global rights to experimental drug sevasemten and positions Servier to expand in rare neurology with closing expected in Q3 2026 pending regulatory clearance.
